Investigational Drug Information for Cannabidivarin
✉ Email this page to a colleague
What is the drug development status for Cannabidivarin?
Cannabidivarin is an investigational drug.
There have been 8 clinical trials for Cannabidivarin.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2022.
The most common disease conditions in clinical trials are Autistic Disorder, Autism Spectrum Disorder, and Disease. The leading clinical trial sponsors are GW Research Ltd, GW Pharmaceuticals Ltd., and Montefiore Medical Center.
There are ninety-seven US patents protecting this investigational drug and four hundred and eighty-three international patents.
Summary for Cannabidivarin
| US Patents | 97 |
| International Patents | 483 |
| US Patent Applications | 669 |
| WIPO Patent Applications | 522 |
| Japanese Patent Applications | 41 |
| Clinical Trial Progress | Phase 2 (2022-02-01) |
| Vendors | 23 |
Recent Clinical Trials for Cannabidivarin
| Title | Sponsor | Phase |
|---|---|---|
| Treatment With Cannabis Oil Containing CBD Only or 20:1 CBD:THC vs. Placebo of Persons With ADHD | Elkana Kohn | Phase 2 |
| Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case Series | Gregory L Smith, MD, MPH | Early Phase 1 |
| CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) | Foundation for Prader-Willi Research | Phase 2 |
Clinical Trial Summary for Cannabidivarin
Top disease conditions for Cannabidivarin
Top clinical trial sponsors for Cannabidivarin
US Patents for Cannabidivarin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Cannabidivarin | ⤷ Sign Up | Crystalline cannabidivarin | S&B Pharma, Inc. (Azusa, CA) | ⤷ Sign Up |
| Cannabidivarin | ⤷ Sign Up | Process to extract and purify .DELTA..sup.9-tetrahydrocannabinol | Axim Biotechnologies, Inc. (New York, NY) | ⤷ Sign Up |
| Cannabidivarin | ⤷ Sign Up | Use of cannabinoids in the treatment of epilepsy | GW Pharma Limited (Vision Park, Histon, Cambridge, GB) | ⤷ Sign Up |
| Cannabidivarin | ⤷ Sign Up | Food and beverage compositions infused with lipophilic active agents and methods of use thereof | ⤷ Sign Up | |
| Cannabidivarin | ⤷ Sign Up | Use of cannabinoids in the treatment of epilepsy | GW Pharma Limited (Vision Park, Histon, Cambridge, unknown) | ⤷ Sign Up |
| Cannabidivarin | ⤷ Sign Up | Use of cannabinoids in the treatment of epilepsy | GW Pharma Limited (Vision Park, Histon, Cambridge, unknown) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Cannabidivarin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Cannabidivarin | European Patent Office | EP3291806 | 2035-05-07 | ⤷ Sign Up |
| Cannabidivarin | Morocco | MA42057 | 2035-05-07 | ⤷ Sign Up |
| Cannabidivarin | World Intellectual Property Organization (WIPO) | WO2016179247 | 2035-05-07 | ⤷ Sign Up |
| Cannabidivarin | Australia | AU2015332212 | 2034-10-14 | ⤷ Sign Up |
| Cannabidivarin | Australia | AU2021204353 | 2034-10-14 | ⤷ Sign Up |
| Cannabidivarin | Brazil | BR112017007777 | 2034-10-14 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
